Logo Helmholtz Munich

Europe united in the fight against type 1 diabetes in children and adolescents


EDENT1FI is a research platform with the goal of stopping type 1 diabetes in its early stages. This groundbreaking project brings together representatives from academic research, industry, and patient organizations from across Europe, including the team from the Fr1da Study led by the Institute for Diabetes Research, Helmholtz Munich.

A paradigm shift in treatment and early detection

Type 1 diabetes is incurable, significantly impacting the quality of life for those affected. Globally, approximately 9 million people are affected, including 300,000 children in Europe. Faced with the increasing incidence of new cases in children and adolescents, especially during the COVID-19 pandemic, and considering that 90 percent of newly diagnosed individuals have no relatives with type 1 diabetes, a paradigm shift in early detection is urgently needed.

With a focus on prevention, EDENT1FI aims to halt the onset of type 1 diabetes in children and adolescents at the preclinical stage. This is intended to be achieved through optimizing existing screening programs and establishing effective early detection in European healthcare systems. In the future, this could ensure widespread access to disease-delaying or preventive measures across Europe.

Read more about the EDENT1FI project here.

Here is the link to the EDENT1FI website.